No impact of disease duration on response to tildrakizumab treatment among patients with moderate‐to‐severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies

• Johannes Griss,
• Gudrun Ratzinger,
• Julia‐Tatjana Maul,
• Wolfgang Weger,
• Diamant Thaçi,
• José Manuel Carrascosa,
• Constanze Jonak

Affiliations

Johannes Griss

Department of Dermatology Medical University of Vienna Vienna Austria

Gudrun Ratzinger

Department of Dermatology Medical University of Innsbruck Innsbruck Austria

Julia‐Tatjana Maul

Department of Dermatology University Hospital Zurich Zurich Switzerland

Wolfgang Weger

Department of Dermatology and Venereology Medical University of Graz Graz Austria

Diamant Thaçi

Institute and Comprehensive Centre for Inflammation Medicine University of Lübeck Lübeck Germany

José Manuel Carrascosa

Department of Dermatology Hospital Universitari Germans Trias i Pujol, IGTP, UAB Badalona Spain

Constanze Jonak

Department of Dermatology Medical University of Vienna Vienna Austria